close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Strand Therapeutics

News headline image
Strand Therapeutics to Present Updated STX-001 Clinical Data Highlighting Durable, Systemic Anti-Tumor Activity, and Showcase STX-003 Trial Design at SITC 2026
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Doses First Patients with STX-003, a Systemic Programmable mRNA Therapy Designed for Tumor-Selective Activation
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Kunal Bhatia as Chief Financial Officer
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics to Present Preclinical Data on Its Programmable mRNA In Vivo CAR-T Platform at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Jeb Keiper to Board of Directors
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Promotes Prashant Nambiar to Chief Scientific Officer and Appoints Ethan Cash as Senior Vice President, Head of Portfolio Management and Program Development
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
From Strand Therapeutics
Via Business Wire
News headline image
Potential First-in-Class Data from Preclinical Program for STX-003, a Programmable mRNA Therapy to Treat Solid Tumor Cancers
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Colleen Wilson as Chief People Officer
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Jay Stella as Chief Business Officer
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million
From Strand Therapeutics
Via Business Wire
News headline image
Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35
From Strand Therapeutics
Via Business Wire
News headline image
Strand Therapeutics Raises $52M in Oversubscribed Series A Round
From Strand Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.